pdf   xlsx method abbreviations

mHCC - 1st line (L1), pembrolizumab based treatment , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.84 [0.71, 1.00]< 10%1 study (1/-)97.7 %NAnot evaluable crucial-
progression or deaths (PFS) 0.87 [0.74, 1.03]< 10%1 study (1/-)94.9 %NAnot evaluable important-

safety endpoints 00

AE (any grade) 1.22 [0.59, 2.52]< 10%1 study (1/-)29.2 %NAnot evaluable non important-
AE (grade 3-4) 1.22 [0.92, 1.62]< 10%1 study (1/-)8.5 %NAnot evaluable non important-
AE leading to death (grade 5) 1.34 [0.30, 6.01]< 10%1 study (1/-)35.3 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 1.84 [1.22, 2.78]< 10%1 study (1/-)0.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons